TransCon CNP for Achondroplasia
(AttaCH Trial)

Recruiting in Palo Alto (17 mi)

+14 other locations

Age: < 18

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Ascendis Pharma Growth Disorders A/S

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial uses TransCon CNP to help children and adolescents with achondroplasia grow their bones properly. It is for those who have already been part of a previous trial. The treatment continues for an extended period.

Eligibility Criteria

This trial is for children and adolescents with achondroplasia who have already been part of a previous TransCon CNP study. They must be able to receive weekly injections, have parental consent, and meet safety criteria from the prior trial. Those unable to complete the study or at risk due to other conditions are excluded.

Inclusion Criteria

My guardian can give me weekly shots and follow the study rules.

I have achondroplasia and finished a trial with TransCon CNP.

My guardian has signed the consent form, and I will too when I'm of age.

+1 more

Exclusion Criteria

I have taken prescription or investigational drugs other than TransCon CNP.

I am not allergic to the trial drug or its components.

I am not using effective birth control and am able to have children.

+2 more

Participant Groups

The long-term safety, tolerability, and effectiveness of TransCon CNP given once a week are being tested in young patients with achondroplasia until they reach skeletal maturity (16 years for females, 18 years for males), confirmed by radiographic imaging.

1Treatment groups

Experimental Treatment

Group I: TransCon CNP 100 mcgExperimental Treatment1 Intervention

TransCon CNP 100 mcg delivered once weekly by subcutaneous injection